

Resource Summary Report

Generated by [dkNET](#) on Aug 8, 2026

Brilliant Violet 421(TM) anti-human CD3

RRID:AB_10962690

Type: Antibody

Proper Citation

BioLegend Cat# 300434, RRID:AB_10962690

Antibody Information

URL: http://antibodyregistry.org/AB_10962690

Proper Citation: BioLegend Cat# 300434, RRID:AB_10962690

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-F

Antibody Name: Brilliant Violet 421(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_10962690

Vendor: BioLegend

Catalog Number: 300434

Alternative Catalog Numbers: 300433

Record Creation Time: 20250819T230829+0000

Record Last Update: 20250820T042448+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD3.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 31 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Galvez NMS, et al. (2026) HIV broadly neutralizing antibody escape dynamics drive the outcome of AAV-vectored immunotherapy in humanized mice. *Immunity*, 59(3), 768.

La C, et al. (2026) In vivo modeling of human ?? T cell ontogeny reveals terminal deoxynucleotidyl transferase as a key regulator of type 3 V?2 T cell development. *Cell reports*, 45(2), 116977.

Chantzoura E, et al. (2026) The Allogeneic FAP-CAR-IL15 iNKT Therapy MiNK-215 Remodels the Tumor Stroma to Enhance Antitumor Immunity. *Cancer immunology research*, 14(2), 243.

Tang E, et al. (2026) Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. *Cancer immunology research*, 14(8), 1292.

Gao T, et al. (2025) Self-assembled patient-derived tumor-like cell clusters for personalized drug testing in diverse sarcomas. *Cell reports. Medicine*, 6(3), 101990.

Lagattuta KA, et al. (2025) The T cell receptor sequence influences the likelihood of T cell memory formation. *Cell reports*, 44(1), 115098.

Shi Y, et al. (2025) pT? enhances mRNA translation and potentiates CAR T cells for solid tumor eradication. *Cell*.

Perez CR, et al. (2025) Library-based single-cell analysis of CAR signaling reveals drivers of in vivo persistence. *Cell systems*, 16(5), 101260.

Neuwirth T, et al. (2025) The polyamine-regulating enzyme SSAT1 impairs tissue regulatory T cell function in chronic cutaneous inflammation. *Immunity*, 58(3), 632.

LaBelle JJ, et al. (2025) Dissecting the immune landscape in pediatric high-grade glioma reveals cell state changes under therapeutic pressure. *Cell reports. Medicine*, 6(5), 102095.

Jayasinghe RG, et al. (2025) Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues. *Cell reports*, 44(5), 115587.

Lin M, et al. (2024) Inflammatory dendritic cells restrain CD11b+CD4+ CTLs via CD200R in human NSCLC. *Cell reports*, 43(2), 113767.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. *Cell reports. Medicine*, 5(7), 101628.

Abdelfattah NS, et al. (2024) T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics. *Immunity*, 57(12), 2945.

Wang J, et al. (2024) LILRB1-HLA-G axis defines a checkpoint driving natural killer cell exhaustion in tuberculosis. *EMBO molecular medicine*, 16(8), 1755.

Pozniak J, et al. (2024) A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. *Cell*, 187(1), 166.

Zhang Y, et al. (2024) Generation of dual-attribute iTNK cells from hPSCs for cancer immunotherapy. *Cell reports methods*, 4(9), 100843.

Yin S, et al. (2024) Patient-derived tumor-like cell clusters for personalized chemo- and immunotherapies in non-small cell lung cancer. *Cell stem cell*, 31(5), 717.

Anderson W, et al. (2023) PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses. *eLife*, 12.

Bird MF, et al. (2023) In vitro sepsis up-regulates Nociceptin/Orphanin FQ receptor expression and function on human T- but not B-cells. *British journal of pharmacology*, 180(17), 2298.